Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC
Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America
The company will be preferred business partner for VPPL in terms of sourcing and supplying key raw materials
The company intends to respond to the two minor observations within the stipulated time
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
The registered capital of the newly founded company is € 50 million
The new campus has been designed as an employee-centred experience and ecosystem zone
The matter of Arbitration between Shilpa Medicare Limited and Celltrion towards supply and distribution agreement
Aarti Drugs has reported total income of Rs. 607.61 crores during the period ended December 31, 2023
Hearing restoration was observed within 30 days of a single administration of AK-OTOF in the initial AK-OTOF-101 study participant
Subscribe To Our Newsletter & Stay Updated
